Abstract
This review articles shows evidence that while PPI treatment may be associated with an increased risk of SARS-CoV-2 infection, recent findings have shown no effect of current PPI treatment on COVID-19 outcome, suggesting that previous inconsistent results were likely due to differences in study design and population. Attempts to transfer patients with COVID-19 infection to H2 histamine blockers are not entirely justified, since despite some positive aspects in the effect on the virus, standard therapeutic doses of drugs for the treatment of gastroesophageal reflux disease and other acid-associated diseases are insufficient to achieve a clinical effect at this category of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
